PLA2G6 gene mutation in autosomal recessive early-onset parkinsonism in a Chinese cohort

Neurology. 2011 Jul 5;77(1):75-81. doi: 10.1212/WNL.0b013e318221acd3. Epub 2011 Jun 22.

Abstract

Objective: Mutations in the PLA2G6 gene at the PARK14 locus have been reported in complicated parkinsonism. To assess the prevalence of and phenotypes associated with PLA2G6 gene mutations, we screened PLA2G6 mutations in a cohort of patients with autosomal recessive early-onset parkinsonism (AREP).

Methods: We selected 12 families with AREP in which the Parkin, PINK1, DJ-1, ATP13A2, and FBXO7 gene mutations had been previously excluded. All patients came from the mainland of China. The entire PLA2G6 coding region and exon-intron boundaries were sequenced from genomic DNA templates. We then performed PET studies on individuals in the pedigree with a homozygous PLA2G6 mutation, and investigated the enzyme activity level of the mutation.

Results: A homozygous missense mutation, c.G991T (p.D331Y), was identified in an autosomal recessive case. A younger sister of the p.D331Y-carrying patient was also homozygous for the mutation, but with no extrapyramidal symptoms. A PET study showed a substantial reduction in dopamine transporter (DAT) binding in the p.D331Y patient, and a slight reduction in DAT binding in his sister. In vitro, we experimentally demonstrate that the D331Y mutation caused an approximately 70%reduction in enzyme activity.

Conclusions: We have confirmed that the PLA2G6 gene allocated PARK14 locus and is associated with AREP.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Animals
  • Asian People / genetics
  • Cell Line, Transformed
  • Cohort Studies
  • DNA Mutational Analysis
  • Family Health
  • Female
  • Gene Expression Regulation / drug effects
  • Green Fluorescent Proteins / genetics
  • Group VI Phospholipases A2 / genetics*
  • Humans
  • Male
  • Mutation, Missense / genetics*
  • Parkinsonian Disorders / diagnostic imaging
  • Parkinsonian Disorders / genetics*
  • Phosphorylcholine / pharmacology
  • Piperazines
  • Positron-Emission Tomography / methods
  • Pyridines
  • Serotonin Antagonists
  • Transfection / methods

Substances

  • Piperazines
  • Pyridines
  • Serotonin Antagonists
  • enhanced green fluorescent protein
  • Phosphorylcholine
  • Green Fluorescent Proteins
  • N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide
  • Group VI Phospholipases A2
  • PLA2G6 protein, human